Patents by Inventor Xiaolian XIE

Xiaolian XIE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240034991
    Abstract: In a method for efficiently inducing reprogramming of human cells into neuronal cells, a concentration of cAMP is increased or an expression of PKA and CREB is up-regulated or an expression of AMPK, ALK2, ALK3, P38, and JNK is inhibited by a single small molecule compound or gene knockout or gene overexpression. In the present disclosure, the induction small molecule compound is single and safe, and has a short induction time, high induction efficiency, definite induction sites and genes, and clear molecular regulation mechanism. The small molecule compound can be applied to the clinical treatment of human neurodegenerative diseases, providing a safer and more efficient treatment method for the neurodegenerative diseases. Since neuronal cells cannot divide and proliferate, the method induces fibroblasts and astrocytes that can divide and proliferate in vitro and in vivo, to continuously obtain a large number of induced neuronal cells in vitro and in vivo.
    Type: Application
    Filed: July 27, 2022
    Publication date: February 1, 2024
    Applicants: GUANGXI UNIVERSITY, Guangxi Benpeng Biotechnology Co., Ltd.
    Inventors: Ben HUANG, Guodong WANG, Dandan ZHANG, Quanhui LIU, Yulian WU, Danwei LV, Jigang HU, Xiaolian XIE
  • Publication number: 20230066648
    Abstract: The present disclosure provides a method for inducing transdifferentiation of somatic cells into mammary epithelial cells in vitro using a small molecule compound. The method includes: inhibiting an expression of TGFbeta R1 and related sites thereof, to induce the transdifferentiation of the somatic cells into the mammary epithelial cells in vitro. The present disclosure fills a gap in the technology of inducing the transdifferentiation of fibroblasts to the mammary epithelial cells using the small molecule compound; the present disclosure also provides a research platform for in vitro researches on a mammary gland bioreactor, mammary gland development and differentiation, breast cancer, and transdifferentiation of the fibroblasts into other types of functional cells.
    Type: Application
    Filed: June 30, 2020
    Publication date: March 2, 2023
    Applicants: GUANGXI UNIVERSITY, Guangxi Benpeng Biotechnology Co., Ltd.
    Inventors: Ben HUANG, Dandan ZHANG, Sheng YE, Shaoqian ZHU, Quanhui LIU, Liangshan QIN, Deshun SHI, Jigang HU, Xiaolian XIE